{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:55:14Z","timestamp":1781898914447,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013365","name":"Sichuan University West China Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115751","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:03:37Z","timestamp":1762571017000},"page":"115751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database"],"prefix":"10.1016","volume":"168","author":[{"given":"Chengze","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2025.115751_bb0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2025.115751_bb0010","first-page":"1216","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Segev","year":"2009","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.intimp.2025.115751_bb0015","first-page":"621","article-title":"Structural basis for therapeutic inhibition of complement C5","volume":"23","author":"Jore","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115751_bb0025","first-page":"1186","article-title":"Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition","volume":"33","author":"Riedemann","year":"2017","journal-title":"Inflarx"},{"issue":"5","key":"10.1016\/j.intimp.2025.115751_bb0030","first-page":"521","article-title":"Low-molecular weight inhibitors of the alternative complement pathway","volume":"27","author":"Schubart","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.intimp.2025.115751_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.612402","article-title":"Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species","volume":"11","author":"Zelek","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115751_bb0040","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.intimp.2025.115751_bb0045","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.intimp.2025.115751_bb0050","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.intimp.2025.115751_bb0055","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.intimp.2025.115751_bb0065","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0070","first-page":"387","article-title":"Impact of eculizumab on exacerbations and hospitalization rates in patients with refractory myasthenia gravis","volume":"61","author":"Howard","year":"2020","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.intimp.2025.115751_bb0075","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.intimp.2025.115751_bb0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite vaccination","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"8","key":"10.1016\/j.intimp.2025.115751_bb0085","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.1893-23","article-title":"Serious bacterial infections associated with eculizumab: a pharmacovigilance study","volume":"63","author":"Okusa","year":"2024","journal-title":"Intern. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115751_bb0090","first-page":"277","article-title":"Neisseria meningitidis vaccination and infection prevention in patients on complement inhibitor therapy","volume":"35","author":"Wolter","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2025.115751_bb0095","first-page":"1183","article-title":"Severe infections associated with eculizumab therapy: a case series","volume":"68","author":"Gurvits","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2025.115751_bb0100","article-title":"Corrigendum: adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115751_bb0105","article-title":"Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115751_bb0110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiology Drug Saf."},{"key":"10.1016\/j.intimp.2025.115751_bb0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.intimp.2025.115751_bb0120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiology Drug Saf."},{"key":"10.1016\/j.intimp.2025.115751_bb0125","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore\u2014a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.intimp.2025.115751_bb0130","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2025.115751_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115751_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.892503","article-title":"Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions","volume":"13","author":"Guan","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115751_bb0145","first-page":"629","article-title":"Halting targeted and collateral damage to red blood cells by the complement system","volume":"43","author":"De Boer","year":"2021","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0150","first-page":"42","article-title":"Complement biology for hematologists","volume":"98","author":"Duval","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115751_bb0155","first-page":"1679","article-title":"Complement C3 inhibition by compstatin Cp40 prevents intra-and extravascular hemolysis of red blood cells","volume":"130","author":"Baas","year":"2020","journal-title":"Journal of clinical investigation"},{"issue":"2","key":"10.1016\/j.intimp.2025.115751_bb0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.transci.2016.04.008","article-title":"The role of complement activation in thrombosis and hemolytic anemias","volume":"54","author":"Chapin","year":"2016","journal-title":"Transfus. Apher. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2025.115751_bb0165","first-page":"343","article-title":"Complement deficiency states and infection: epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency","volume":"63","author":"Ross","year":"1984","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.intimp.2025.115751_bb0170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0167-5699(91)90003-C","article-title":"Complement deficiency and disease","volume":"12","author":"Morgan","year":"1991","journal-title":"Immunol. Today"},{"issue":"17","key":"10.1016\/j.intimp.2025.115751_bb0175","first-page":"2167","article-title":"Vaccine interactions between complement inhibitors and pathogens to their ability to establish infection with particular emphasis on Neisseria","volume":"26","author":"Blom","year":"2008","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.intimp.2025.115751_bb0180","first-page":"372","article-title":"Interactions between Neisseria meningitidis and the complement system","volume":"15","author":"Sim","year":"2007","journal-title":"Trends Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0185","first-page":"1291","article-title":"Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies","volume":"78","author":"Hellerud","year":"2010","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0190","first-page":"131","article-title":"Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond","volume":"98","author":"Peffault de Latour","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"37","key":"10.1016\/j.intimp.2025.115751_bb0195","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104347118","article-title":"Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons","volume":"118","author":"Keshari","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2025.115751_bb0200","article-title":"Persistent complement dysregulation with signs of thromboinflammation in active long covid","volume":"383(6673):eade7942","author":"Cervia-Hasler","year":"2024","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2025.115751_bb0205","first-page":"1133","article-title":"Pharmacogenomics, pharmacokinetics, and pharmacodynamics: interaction with biological differences between men and women","volume":"171","author":"Franconi","year":"2014","journal-title":"Brit J Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115751_bb0210","first-page":"567","article-title":"Gender differences in drug metabolism and pharmacokinetics","volume":"40","author":"Li","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"7","key":"10.1016\/j.intimp.2025.115751_bb0215","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3390\/jcm10071441","article-title":"Sex-related differences in drugs with anti-inflammatory properties","volume":"10","author":"Baumg\u00e4rtel","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115751_bb0220","first-page":"517","article-title":"The role of the complement system in sex differences in the myocardial inflammatory response to acute injury","volume":"23","author":"Kher","year":"2005","journal-title":"Shock"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2025.115751_bb0225","first-page":"132","article-title":"Sex differences and estrogen modulation of the cellular immune response after injury","volume":"253","author":"Karavitis","year":"2008","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115751_bb0230","first-page":"526","article-title":"Gender differences in sepsis: cardiovascular and immunological aspects","volume":"5","author":"Chaudry","year":"2014","journal-title":"Virulence"},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0235","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/heartjnl-2018-313492","article-title":"Fixed-dose combination antihypertensives and risk of medication errors","volume":"105","author":"Moriarty","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.intimp.2025.115751_bb0240","article-title":"Systems pharmacology of adverse event mitigation by drug combinations","volume":"5(209):209ra152","author":"Azeloglu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115751_bb0245","article-title":"Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects","volume":"16","author":"Kafetzopoulos","year":"2025","journal-title":"Front. Psych."},{"issue":"5","key":"10.1016\/j.intimp.2025.115751_bb0250","first-page":"408","article-title":"Longitudinal effects of self-report pubertal timing and Menarcheal age on adolescent psychological and behavioral outcomes in female youths from northern Taiwan","volume":"58","author":"Tsai","year":"2017","journal-title":"Pediatrics & Neonatology."},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0255","article-title":"Sex-specific and gender-specific aspects in patient-reported outcomes","volume":"5","author":"Blum","year":"2020","journal-title":"ESMO Open."},{"issue":"6","key":"10.1016\/j.intimp.2025.115751_bb0260","first-page":"103","article-title":"Social psychological aspects of reporting behavior: lifetime depressive episode reports","volume":"30","author":"Aneshensel","year":"1987","journal-title":"Society And Social Behavior"},{"issue":"2","key":"10.1016\/j.intimp.2025.115751_bb0265","first-page":"54","article-title":"The effects of response bias on self-reported quality of life among childhood cancer survivors","volume":"12","author":"Diller","year":"2007","journal-title":"Quality Of Life Research"},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0270","first-page":"304","article-title":"Gender differences in the reporting of physical and somatoform symptoms","volume":"60","author":"Kroenke","year":"1998","journal-title":"Psychosomatic Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/biom14010039","article-title":"The role of the complement system in the pathogenesis of infectious forms of hemolytic uremic syndrome","volume":"14","author":"Avdonin","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.intimp.2025.115751_bb0280","first-page":"67","article-title":"The role of complement in post-transfusion hemolysis and hyperhemolysis reaction","volume":"33","author":"Roumenina","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.intimp.2025.115751_bb0285","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115751_bb0290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neubiorev.2016.05.035","article-title":"Immunoadolescence: Neuroimmune development and adolescent behavior","volume":"70","author":"Brenhouse","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0295","first-page":"25","article-title":"Sex differences in immune responses and immune reactivity to stress in adolescents","volume":"6","author":"Kang","year":"2004","journal-title":"Biol. Res. Nurs."},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0300","first-page":"697","article-title":"Clinical and economic burden of adverse drug reactions","volume":"344","author":"Sultana","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115751_bb0305","first-page":"132","article-title":"Landscape of urine biomarkers for bladder cancer: molecular function, cell-of-origin, and bibliometric trend","volume":"10","author":"Liu","year":"2024","journal-title":"Oncology and Translational Medicine"},{"issue":"2","key":"10.1016\/j.intimp.2025.115751_bb0310","first-page":"228","article-title":"Age-related decline in immune function and susceptibility to infection in older adults","volume":"68","author":"Nguyen","year":"2020","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.intimp.2025.115751_bb0315","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2025.115751_bb0320","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/ot9.0000000000000089","article-title":"Exceptional and durable response with pembrolizumab in a patient with microsatellite stable metastatic castrate-resistant prostate cancer: high tumor mutational burden and circulating tumor DNA clearance as predictive biomarkers","volume":"11","author":"Au","year":"2025","journal-title":"Oncology and Translational Medicine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925017394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925017394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:45:49Z","timestamp":1781898349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925017394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":64,"alternative-id":["S1567576925017394"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115751","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115751"}}